AI-Engineered "Intrabodies" Breach Cellular Barriers to Target Alzheimer’s and MND at the Source

University of Essex researchers use AI to create antibody fragments that work inside cells. A major breakthrough for treating MND, Parkinson's, and Alzheimer's.

By: AXL Media

Published: Mar 19, 2026, 12:21 PM EDT

Source: Information for this report was sourced from University of Essex

Overcoming the Cellular Barrier to Antibody Therapy

Antibodies have long been a cornerstone of modern medicine, but their application in neurodegenerative research has been severely limited by a fundamental biological constraint: they typically only function outside of cells. Because diseases like Alzheimer’s, Parkinson’s, and MND are driven by protein misfolding and aggregation inside neurons, traditional antibody treatments often fail to reach their intended targets. New research published in Nature Communications has successfully bypassed this hurdle by engineering antibody fragments specifically designed to survive the harsh internal environment of the human cell.

The Role of Electrical Charge in Molecular Stability

The breakthrough, led by Dr. Caitlin O’Shea and Dr. Gareth Wright, centered on the discovery that standard antibodies possess the "wrong" electrical charge to exist indoors. When placed inside a cell, these molecules typically stick together and become ineffective. By comparing millions of antibodies with native human intracellular proteins, the Essex team identified the precise charge modifications required to keep these fragments stable. This discovery allowed the researchers to transition from traditional antibodies to "intrabodies," which remain soluble and active within the cellular cytoplasm.

Harnessing Nobel Prize-Winning AI for Protein Redesign

To implement these findings at scale, the team utilized advanced protein-design software developed by Nobel laureate David Baker. This AI-driven approach enabled the scientists to analyze and redesign 672 different antibody fragments, ensuring each possessed the optimal stability and charge to function as an intracellular tool. This massive library of redesigned molecules can now be used to target a wide array of disease-causing proteins that were previously considered "undruggable" due to their location within the cell.